Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:Optimal testing for RET fusionsDNA NGS vs RNA NGSMolecular testing workflowsUsing new selective RET inhibitors to treat patients with RET fusion–positive NSCLCCommon toxicities with new selective RET inhibitorsInterdisciplinary communication between medical oncologists and pathologistsPresenters:Dara L. Aisner, MD, PhDAssociate ProfessorDepartment of PathologyDirector, Molecular PathologyUniversity of ColoradoAurora, ColoradoJoshua Bauml, MDAssistant Professor of MedicineDivision of Hematology/OncologyPerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program, including associated downloadable slidesets:https://bit.ly/2Fsq9Wv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.